SBC Medical Group Holdings Inc

SBC Medical Group Holdings Inc(SBC)股票分析

$4.180

+0.166 (+3.98%)收盤時

Loading chart…
High
4.194
Open
4.010
VWAP
4.13
Vol
163.09K
Mkt Cap
Low
4.010
Amount
673.22K
EV/EBITDA, TTM
3.40

SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.

AI analysis of SBC Medical Group Holdings Inc (SBC)

buy

SBC Medical Group Holdings Inc is a good buy right now due to its recent Q2 2026 earnings report showing a revenue increase of 13% year-over-year to $49 million, alongside a robust adjusted EBITDA growth of 32% to $20 million. The stock is currently priced at $4.05, which is significantly below the analyst's target price of $8, suggesting a potential upside of 97.5%. Additionally, the forward P/E ratio of 9.30 indicates that the stock is undervalued compared to its earnings potential. However, a risk to consider is the recent earnings surprise of -16.67%, which may indicate volatility in performance expectations.

估值指標

The current forward P/E ratio for SBC Medical Group Holdings Inc (SBC) is 9.23, compared to its 5-year average forward P/E of 4.53.

Forward P/E

Overvalued
5Y Average P/E
4.53
Current P/E
9.23
高估
8.49
低估
0.57

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
0.88
Current EV/EBITDA
3.40
高估
2.38
低估
-0.61

Forward P/S

Fair
5Y Average P/S
1.31
Current P/S
1.98
高估
2.42
低估
0.19

事件時間軸

2026-08-13 (ET)

07:00:00

SBC Medical Reports Q2 Revenue of $49M

2026-05-14 (ET)

06:40:00

SBC Medical Reports Q1 Revenue of $43M, Below Expectations

2026-03-27 (ET)

16:30:00

Major Averages Drop Due to Strait of Hormuz Incidents

12:00:00

Major Averages Decline Amid Middle East Tensions

06:50:00

SBC Medical Reports 11% Increase in Average Revenue per Customer in Q4

資訊

SBC FAQ — answered by Alphio AI

SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics. It operates in the Industrials sector.

SBC Medical Group Holdings Inc is a good buy right now due to its recent Q2 2026 earnings report showing a revenue increase of 13% year-over-year to $49 million, alongside a robust adjusted EBITDA growth of 32% to $20 million. The stock is currently priced at $4.05, which is significantly below the analyst's target price of $8, suggesting a potential upside of 97.5%. Additionally, the forward P/E ratio of 9.30 indicates that the stock is undervalued compared to its earnings potential. However, a risk to consider is the recent earnings surprise of -16.67%, which may indicate volatility in performance expectations.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始